Industry News
Research, Science & Manufacturer Updates
Immune Globulin Articles
The U.S. Food and Drug Administration has instructed manufacturers to add information to the current boxed warning in the labeling of all intravenous immune globulin (IVIG) products, and add a similar standardized boxed warning for all subcutaneous and intramuscular IG products.
With the objective of evaluating the safety and tolerability of intravenous immune globulin (IVIG) as a treatment for neuromyelitis optica (NMO), a team of Spanish investigators administered IVIG (0.7 g/kg body weight for three days) every two months to eight patients meeting Wingerchuk’s revised diagnostic criteria for the disorder.
Results from a new study in patients with early Alzheimer’s disease showed a short course of intravenous immune globulin slows the disease’s progression.
A meta-analysis showed IVIG was as effective as plasma exchange in reducing Guillain Barré syndrome disability scores, with no significant difference in adverse events.
A multinational team of investigators exposed cultured neurons with intravenous immunoglobulin (IVIG) to evaluate its effect on downstream signaling pathways involved in neuronal cell death.
Recent studies suggest that the divergent outcomes in Alzheimer’s disease clinical studies of intravenous immune globulin (IVIG) may be due to differences in temporal administration and administered dosages.
An investigational 10% liquid intravenous immunoglobulin product currently under U.S. regulatory review for marketing approval appears to be safe and effective for prophylactic treatment of patients with primary immunodeficiency disorders.
Canadian scientists are working on an intravenous treatment for Alzheimer’s that could halt the progression of the disease and improve cognitive functions.
The U.S.Food and Drug Administration has approved subcutaneous Gammagard Liquid 10% for patients with primary immunodeficiency.
SL Behring has developed a pharmacokinetic model that shows how the body absorbs, distributes, metabolizes and eliminates immunoglobulin following subcutaneous administration.